| Primary |
| Chronic Obstructive Pulmonary Disease |
25.9% |
| Oxygen Supplementation |
18.5% |
| Product Used For Unknown Indication |
11.1% |
| Neonatal Respiratory Distress Syndrome |
7.4% |
| Vocal Cordectomy |
7.4% |
| Bronchopulmonary Dysplasia |
3.7% |
| Cardiac Failure Congestive |
3.7% |
| Dyspnoea |
3.7% |
| Hypoxia |
3.7% |
| Maxillofacial Operation |
3.7% |
| Pleural Effusion |
3.7% |
| Status Epilepticus |
3.7% |
| Upper Respiratory Tract Infection |
3.7% |
|
| Thermal Burn |
27.3% |
| No Adverse Event |
12.1% |
| Medication Error |
6.1% |
| Respiratory Distress |
6.1% |
| Acute Respiratory Distress Syndrome |
3.0% |
| Burns Third Degree |
3.0% |
| Cardiac Arrest |
3.0% |
| Haemolytic Anaemia |
3.0% |
| Hypercapnia |
3.0% |
| Hypoxia |
3.0% |
| Myositis |
3.0% |
| Overdose |
3.0% |
| Oxygen Saturation Decreased |
3.0% |
| Pharmaceutical Product Complaint |
3.0% |
| Pneumocephalus |
3.0% |
| Procedural Complication |
3.0% |
| Product Odour Abnormal |
3.0% |
| Pyrexia |
3.0% |
| Respiratory Failure |
3.0% |
| Respiratory Fume Inhalation Disorder |
3.0% |
|
| Secondary |
| Maintenance Of Anaesthesia |
13.3% |
| Drug Use For Unknown Indication |
10.7% |
| Asthma |
9.3% |
| General Anaesthesia |
9.2% |
| Anaesthesia |
8.7% |
| Induction Of Anaesthesia |
8.7% |
| Chronic Obstructive Pulmonary Disease |
8.6% |
| Drug Exposure During Pregnancy |
6.0% |
| Product Used For Unknown Indication |
5.1% |
| Premedication |
3.3% |
| Anaesthesia Procedure |
2.4% |
| Hypertension |
2.2% |
| Maternal Exposure Timing Unspecified |
1.9% |
| Prophylaxis |
1.8% |
| Pulmonary Arterial Hypertension |
1.8% |
| Anaesthesia Reversal |
1.4% |
| Analgesia |
1.4% |
| Nerve Block |
1.4% |
| Wheezing |
1.4% |
| Hypotension |
1.3% |
|
| Mesothelioma |
12.1% |
| Vomiting |
7.5% |
| Tachycardia |
6.5% |
| Migraine With Aura |
5.6% |
| Respiratory Arrest |
5.6% |
| Tachypnoea |
5.6% |
| Urticaria |
5.6% |
| Ventricular Tachycardia |
5.6% |
| Wheezing |
5.6% |
| Chronic Obstructive Pulmonary Disease |
4.7% |
| Emphysema |
4.7% |
| Hypotension |
4.7% |
| Respiratory Distress |
4.7% |
| Respiratory Failure |
3.7% |
| Rhabdomyolysis |
3.7% |
| Diarrhoea |
2.8% |
| Epistaxis |
2.8% |
| Oxygen Saturation Decreased |
2.8% |
| Pallor |
2.8% |
| Premature Baby |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
17.1% |
| Chronic Obstructive Pulmonary Disease |
15.0% |
| Drug Use For Unknown Indication |
14.9% |
| Pulmonary Arterial Hypertension |
10.6% |
| Hypertension |
4.7% |
| Asthma |
4.0% |
| Pulmonary Hypertension |
3.7% |
| Pain |
3.7% |
| Induction Of Anaesthesia |
2.9% |
| Emphysema |
2.8% |
| Maintenance Of Anaesthesia |
2.6% |
| Osteoporosis |
2.6% |
| Prophylaxis |
2.4% |
| Anaesthesia |
2.3% |
| Dyspnoea |
2.1% |
| Depression |
1.9% |
| Diabetes Mellitus |
1.8% |
| General Anaesthesia |
1.8% |
| Rheumatoid Arthritis |
1.6% |
| Non-small Cell Lung Cancer |
1.5% |
|
| Dyspnoea |
13.5% |
| Death |
11.6% |
| Pneumonia |
9.8% |
| Vomiting |
7.8% |
| Weight Decreased |
7.2% |
| Respiratory Failure |
6.1% |
| Drug Ineffective |
4.5% |
| Weight Increased |
4.5% |
| Urinary Tract Infection |
3.3% |
| Chronic Obstructive Pulmonary Disease |
3.1% |
| Sepsis |
3.1% |
| Vision Blurred |
3.1% |
| Wheezing |
3.1% |
| Oedema Peripheral |
3.0% |
| Pulmonary Hypertension |
3.0% |
| Tremor |
2.9% |
| Syncope |
2.9% |
| Malaise |
2.6% |
| Nausea |
2.6% |
| Thrombocytopenia |
2.6% |
|
| Interacting |
| Oxygen Supplementation |
75.0% |
| Testicular Germ Cell Cancer |
25.0% |
|
| Chest Pain |
50.0% |
| Urine Output Decreased |
50.0% |
|
